into question the common assumption that the layers of the myelin sheath have a high electrical resistance.
dominant-negative interactions (the mutation interferes with the product of the normal allele) or toxic effects (the mutation has a deleterious effect on the cell). PMP22 to cause growth-arrest, however, may be unrelated to how PMP22 mutations cause neuropathy, as PMP22 and P 0 Mutations in these genes in humans cause dominantly overexpression of PMP22 in vivo causes excessive proliferation of Schwann cells, not growth arrest (Magyar inherited forms of demyelinating CMT (CMT1A and CMT1B), as well as other forms of demyelinating neuroet al., 1996; Sereda et al., 1996) .
pathy that differ so remarkably in severity that they have traditionally been classified as distinct diseases ( Table  Mutations in Myelin-Related Genes Cause Demyelination 1). The most common inherited neuropathies are CMT1A and hereditary neuropathy with liability to pressure pal-A robust interaction between the investigations of myelin and inherited demyelinating diseases of mice and sies (HNPP), which are caused by the duplication and deletion, respectively, of a 1.5 Mb segment of chromohumans has led to the discovery of the molecular basis of these diseases (reviewed by Suter and Snipes, 1995) . some 17 containing PMP22 (Suter and Snipes, 1995) . Overexpressing or underexpressing the PMP22 gene After myelin was shown to contain PLP, myelin basic protein (MBP), and PMP22, naturally occurring mutaalone causes demyelination in rodents, demonstrating that PMP22 is the critical gene in the 1.5 Mb segment tions of their genes were shown to cause respectively the jimpy (jp), shiverer (sh), and Trembler (Tr) mutations Sereda et al., 1996) . Consistent with the changes in gene dosage, the amount of PMP22 in mice, and subsequently human diseases (Table 1) . In mice these naturally occurring mutations have now been protein in compact myelin is increased in CMT1A and decreased in HNPP (Vallat et al., 1996) , indicating that augmented by gene "knockouts," which are particularly valuable as the targeting vector typically creates a lossaltered levels of PMP22 destabilize the myelin sheath. Missense mutations in PMP22 are rare, and the resultant of-function allele. The reason that these null alleles are so important relates to the following argument: if the phenotypes are typically much more severe than in HNPP, ranging from typical CMT1 to even more severe phenotype caused by a null allele is milder than that caused by another allele, then the latter must cause forms (Dejerine-Sottas disease). Warner et al. (1996) argue that P 0 mutations in humans more than a simple loss of function. Such comparisons can be directly made in murine mutations of Pmp22 cause demyelination because they adversely affect the function of P 0 as an adhesion molecule. They postulate and Plp; the same reasoning can be applied to human mutations of PMP22, PLP, and P 0 . How mutations cause that mutations that result in a simple loss of function Noncompact myelin is found at the paranodes in the mammalian CNS, but it lacks some of the molecular specializations found in noncompact myelin of the PNS myelin, such as MAG and E-cadherin. Although MAG is illustrated as interacting homophilically, this is unproven.
cause CMT1B, whereas mutations that alter the ability chief manifestation is spasticity of the legs. As in mice, PLP deletions in humans result in a milder phenotype of P0 to interact with other P0 molecules cause more severe phenotypes owing to dominant-negative effects.
than most missense mutations, and missense mutations that affect less conserved residues tend to cause a The problem with their interpretation is that the patients affected by their best example of a loss-of-function mumilder phenotype. The deleterious effect of these missense mutations, furthermore, is toxic; it cannot be tation (a premature truncation of the extracellular domain) have a milder phenotype than any other CMT1B caused by dominant-negative interactions in the usual sense because each cell (even in females) expresses patient. Because other CMT1B patients have a much more severe phenotype, the responsible mutations only a single PLP gene. These observations have been extended to a cellular probably cause more than a simple loss of function. Further, the range of phenotypes in different kindreds level by expressing various PLP mutants and their DM-20 counterparts separately in COS-7 cells (Gow and suggests that different P0 mutations may have distinct effects. Dominant-negative interactions of P0 mutations Lazzarini, 1996) . Both PLP and DM-20 fail to reach the cell surface when PLP (human) and Plp (mouse) have been demonstrated (Wong and Filbin, 1996) , but other explanations, such as the misfolding of the mumutations causing severe phenotypes are expressed, whereas DM-20 but not PLP reaches the cell surface tated protein, have not been evaluated.
The analysis of P 0 Ϫ/Ϫ and P 0 ϩ/Ϫ mice is also consistent when PLP and Plp mutations causing milder phenotypes are expressed. When DM-20 and PLP do not reach the with an adhesive role of P 0 . Myelinating Schwann cells in P 0 Ϫ/Ϫ mice form a multilamellar myelin-like sheath cell surface, they accumulate in the endoplasmic reticulum; this could be the basis for the toxic gain of function around axons, but the myelin fails to compact normally. Myelination in P 0 ϩ/Ϫ mice, in contrast, is essentially norof these mutants. These results also suggest that the ability of DM-20 to accumulate in myelin may be critical mal for several months, but aging animals develop a demyelinating neuropathy. Thus, a single P 0 allele allows to reducing the severity of the phenotype. Cx32 myelin to compact normally during development but appears to be insufficient to maintain myelin compaction CMTX is distinct from CMT1 and is caused by mutations of the gene encoding the gap junction protein Cx32 through adulthood. Plp (Suter and Snipes, 1995) . Nearly 90 different mutations in Cx32 cause CMTX, and in most kindreds, the disease The first clue that missense Plp mutations cause more than a loss of function was the realization that different is X-linked dominant, with males affected earlier and more severely than females. The range of phenotypes jp alleles cause phenotypes of varying severity (Nave and Boespflug-Tanguy, 1996) . The jp and jp msd alleles is not nearly as dramatic as in other inherited demyelinating diseases, but frame-shift mutations and some precause a severe phenotype: many oligodendrocytes undergo apoptosis, little myelin is produced, and the animature truncations may cause more severe phenotypes. The functional effects of a few mutations have been mals die at a young age. The phenotype of jp rsh , in contrast, is relatively mild: oligodendrocytes do not die, a determined by expressing them in Xenopus oocytes and HeLa cells, which are standard assay systems for this significant amount of myelin is produced, and the animals are long-lived. Initially, the basis for these different purpose (Bruzzone et al., 1996; Omori et al., 1996) . Most Cx32 mutants tested to date do not form functional phenotypes was unclear. The jp msd mutation affects a residue that is highly conserved in other DM-20 family gap junctions with wild-type Cx32, indicating that these mutations cause a loss of Cx32 function. Immature members, whereas the jp rsh mutation affects a less conserved residue, so that more severe phenotypes might Cx32 Ϫ/Ϫ mice have normal-appearing myelin but develop a demyelinating neuropathy with age (Nelles et owe to a more complete loss of function. In this case, a PLP transgene should rescue the phenotype of jp al., 1996), demonstrating that a loss-of-function allele is sufficient to cause demyelination. Some mutants, howmice. This was not observed, indicating that severe phenotypes probably represent instead a dominant, deleteever, can form functional gap junctions, so it is unclear how they could cause demyelination. One possible exrious effect of Plp mutations. The analysis of Plp Ϫ/Ϫ mice provides a more rigorous proof, as these mice have a planation is that these Cx32 mutants have dominantnegative interactions with other connexins, as has been mild to minimal phenotype (Boison and Stoffel, 1994; Klugmann et al., 1997 [this issue]) . The mice are fertile demonstrated in oocytes. It remains to be demonstrated that myelinating Schwann cells express other members and long-lived, although CNS myelin is poorly compacted and has an abnormal periodicity, perhaps reof the connexin family, and that Cx32 mutants have dominant-negative interactions with them. flecting reduced adhesion between the extracellular surfaces in the absence of PLP.
UDP-galactose ceramide galactosyltransferase (cgt)
The targeted disruption of cgt provides the unpreceMissense PLP mutations in humans also cause a wide range of abnormalities, mainly seen in males, as the PLP dented opportunity to perturb the lipid components of myelin (Bosio et al., 1996; Coetzee et al., 1996) . Because gene is on the X chromosome (Nave and BoespflugTanguy, 1996) . The connatal form of Pelizaeus-Merz-CGT is necessary for the synthesis of Gal-C and sulfatide, these glycolipids are completely absent in cgt Ϫ/Ϫ bacher disease (PMD) is the most severe; affected males have severe psychomotor impairment and typically die mice, although the levels of glucoceramides are elevated. cgt Ϫ/Ϫ mice develop neurological signs with the before 10 years of age. Males affected with the classical form of PMD, in contrast, have much milder motor and onset of myelination, and most die between 18 and 30 days. Surprisingly, except for the splitting of some CNS intellectual defects as well as longer lives. The mildest phenotype is spastic paraplegia, so named because the myelin sheaths, most CNS and PNS myelin sheaths have of Gal-C and sulfatide increases the capacitance of the Yoshida, M., and Colman, D.R. (1996) . Neuron 16, 1115 Neuron 16, -1126 myelin, leading to a normal-appearing but functionless myelin sheath.
Wrapping Up
The study of myelin and inherited demyelinating disorders has converged to a common point: the biology of myelin-forming cells. Once the subject of a lively debate, all of the known mutations causing demyelination have turned out to affect genes expressed by myelin-forming cells; mutations of neuronal genes have not yet been shown to cause any inherited demyelinating disease. The consequences of these mutations, moreover, must ultimately be deciphered in the myelinating cells. This will be challenging, given the large number of genes that cause demyelination, the different effects of mutations that have been described, the sheer number of mutations, and the possibility of macromolecular interactions in the myelin sheath. Yet, determining the molecular mechanisms of demyelination is a powerful way to understand the function of myelin and the clearest way to a rational basis for classifying and treating these disorders.
